Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer

International Journal of Clinical Oncology

Volumn 17, Issue 3, 2012, Pages 204-211

  Narita, Shintaro ^a   Tsuchiya, Norihiko ^a   Yuasa, Takeshi ^b   Maita, Shinya ^a   Obara, Takashi ^a   Numakura, Kazuyuki ^a   Tsuruta, Hiroshi ^a   Saito, Mitsuru ^a   Inoue, Takamitsu ^a   Horikawa, Yohei ^a   Satoh, Shigeru ^a   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Chemotherapy; Docetaxel; Prostate cancer; Single nucleotide polymorphism

Indexed keywords

CARBOPLATIN; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN;

ABCB1 GENE; ABCG2 GENE; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYP3A5 GENE; DIARRHEA; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GENE; GENOTYPE; HETEROZYGOTE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; MALE; MAP4 GENE; MAPT GENE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; XRCC1 GENE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PROGNOSIS; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 84862890909     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0275-6     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
2. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520
3. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
4. Regan MM, O'Donnell EK, Kelly WK et al (2010) Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Ann Oncol 21:312-318
5. Soga N, Kato M, Nishikawa K et al (2009) Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. Int J Clin Oncol 14:130-135
6. Tsuchiya N, Wang L, Suzuki H et al (2006) Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24:1982-1989
7. Tsuchiya N, Inoue T, Narita S et al (2008) Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vin-blastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol 180:2389-2395
8. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159
9. Japanese Urological Association and the Japanese Society of Pathology (2001) General rule for clinical and pathological studies on prostatic cancer. Kanehara, Tokyo
10. Halabi S, Small EJ, Kantoff PW et al (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232-1237
11. Halabi S, Vogelzang NJ, Kornblith AB et al (2008) Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26:2544-2549
12. Kikuno N, Urakami S, Nakamura S et al (2007) Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 51:1252-1258
13. Beer TM, Ryan CW, Venner PM et al (2008) Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112:326-330
14. Sierko E, Wojtukiewicz MZ (2004) Platelets and angiogenesis in malignancy. Semin Thromb Hemost 30:95-108
15. Helley D, Banu E, Bouziane A et al (2009) Platelet microparti-cles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol 56:479-484
16. Kimchi-Sarfaty C, Oh JM, Kim IW et al (2007) A ''silent'' polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528
17. Sissung TM, Baum CE, Deeken J et al (2008) ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with doce-taxel. Clin Cancer Res 14:4543-4549